【无锡途深智合人工智能科技有限公司完成数百万元天使轮融资，引领AI蛋白质设计新纪元】
近日，国内生物科技领域的创新之星——「途深智合」宣布成功获得诚美资本投资的数百万元天使轮融资。这家于2023年创立的人工智能科技公司，专注于AI蛋白质设计与优化，正逐步崭露头角，为合成生物学领域带来革命性的技术突破。
「途深智合」不仅在人工智能技术上独树一帜，更在生物科技应用上展现出深厚的潜力。公司致力于通过AI算法，对蛋白质进行精准设计与优化，为合成生物领域的创新提供强大的工具。此次融资所得资金，将主要用于实验室的扩建和专业团队的建设，以加速技术研发与产品化进程。
作为一家致力于解决合成生物领域新问题的公司，「途深智合」的解决方案和新产品将为相关产业打开新的可能。其人工智能驱动的蛋白质设计技术，有望为医药、环保、能源等多个领域带来颠覆性的改变，推动生物科技迈入智能设计的新时代。
诚美资本的投资，不仅是对「途深智合」技术实力的认可，也是对该公司未来发展前景的积极展望。随着生物科技与人工智能的深度融合，「途深智合」有望成为行业内的领军企业，引领中国乃至全球的蛋白质设计与合成生物技术革新。
此次融资事件再次证明，科技创新在生物科技领域的应用正在以前所未有的速度发展，而「途深智合」正是这一趋势的有力推动者。未来，该公司将以更强大的研发实力，为全球生物科技的进步贡献力量。
英语如下：
**News Title:** “TuShenZhiHe Secures Million-Dollar Angel Round Investment, Pioneering a New Era in AI Protein Design”
**Keywords:** AI Protein Design, TuShenZhiHe, Angel Financing Round
**News Content:**
**Wuxi TuShenZhiHe Artificial Intelligence Technology Co., Ltd. has recently completed an angel round financing of millions of yuan, ushering in a new era in AI-driven protein design.**
The rising star in China’s biotech sector, ‘TuShenZhiHe’, announced that it has successfully secured millions of yuan in angel financing from Chengmei Capital. Founded in 2023, this AI technology company specializes in AI protein design and optimization, gradually making its mark with groundbreaking technological advancements in synthetic biology.
TuShenZhiHe distinguishes itself not only in AI technology but also demonstrates profound potential in biotech applications. The company is dedicated to precisely designing and optimizing proteins using AI algorithms, providing a powerful tool for innovation in the synthetic biology field. Funds from this financing round will primarily be allocated to expanding laboratories and building a professional team to accelerate research and development, as well as product commercialization.
As a company committed to tackling new challenges in synthetic biology, TuShenZhiHe’s solutions and new products will unlock new possibilities for the industry. Its AI-driven protein design technology holds the promise of transformative changes in sectors like pharmaceuticals, environmental protection, and energy, propelling biotechnology into an era of intelligent design.
Chengmei Capital’s investment not only acknowledges TuShenZhiHe’s technical prowess but also reflects a positive outlook on the company’s future prospects. With the深度融合 of biotechnology and AI, TuShenZhiHe is poised to become a leading player in the industry, driving protein design and synthetic biology innovation in China and globally.
This financing event underscores the unprecedented pace of innovation in biotechnology through the application of technology, with TuShenZhiHe playing a pivotal role. In the future, the company will leverage its enhanced R&D capabilities to contribute to the advancement of global biotechnology.
【来源】https://36kr.com/p/2686282258132355
Views: 5